A major U.S. drug manufacturing plant did not properly investigate cat hair, pests, and other problems, the FDA found in a ...

The shooter, identified by authorities as Patrick Joseph White, appears to have been captured in security camera footage ...

The Trump administration can slash $783 million of research funding in its push to cut federal diversity, equity and ...

On September 10, join this virtual event to hear industry-leading insights to improve operational efficiency and regulatory ...

Ionis Pharmaceuticals won FDA approval for a drug that prevents painful swelling attacks triggered by a rare genetic ...

Neuroscientists have long held that the brain reorganizes itself when a body part is amputated. A new study says that’s not ...

Soleno Therapeutics CEO responds to a 415-page short-seller report alleging safety issues tied to the company's newly ...

The FDA's controversial rejection of a skin cancer therapy from Replimune Group has prompted Krystal Biotech to shut down of a clinical trial involving a similar drug.

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's proven effectiveness ...

This week on "The Readout LOUD," we discuss Viking Therapeutics' obesity flop and dish on the growing "pharm to table" movement.

This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.

After deaths and FDA setbacks, Sarepta abandoned LGMD gene therapy, leaving families desperate and patients without long-promised treatments.